Dupilumab - Standard Dose

DRUG3 trials

Sponsors

Johns Hopkins University, Northwestern University, Children's Hospital of Fudan University

Conditions

Atopic DermatitisChronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Eosinophilic Gastrointestinal Disorders (EGIDs)Smell Loss

Phase 4

Dupilumab De-escalation in Pediatric Atopic Dermatitis

RecruitingNCT06116526

Johns Hopkins UniversityAtopic Dermatitis

Start: 2024-04-01End: 2027-04-30Target: 30Updated: 2026-01-13

Unknown Phase

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

RecruitingNCT06892704

Northwestern UniversityChronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss

Start: 2025-05-01End: 2027-12-31Target: 30Updated: 2025-05-14

Dupilumab Therapy for EGIDs

RecruitingNCT07257835

Children's Hospital of Fudan UniversityEosinophilic Gastrointestinal Disorders (EGIDs)

Start: 2025-01-01End: 2027-12-01Target: 20Updated: 2025-12-02